Clinical Momentum Psilera has ramped up funding and regulatory activity, including an oversubscribed $8.8M seed extension in May 2026 and NIH grant support, signaling a clear path toward IND-enabling studies and clinic-ready assets that can attract CROs, contract research partnerships, and translational services.

Neuroplastogen Focus The company is pursuing next-generation neuroplastogens and psychedelic therapies with a novel synthetic platform, presenting opportunities to license or co-develop platforms, contract synthesis, and specialized discovery collaborations for neuropsychiatric indications.

Strategic Partnerships Recent IP licensing with Atai/Beckley and a DMT patent portfolio sale indicate willingness to engage in strategic deals; target potential alliances around platform access, joint development, and non-dilutive grant-supported collaborations.

Clinical Leadership Appointment of a Chief Medical Officer and progression toward IND-enabling work highlights a sales angle to engage medical affairs, clinical development services, and advisory partnerships for trial design, regulatory strategy, and biomarker collaborations.

Funding Readiness With a credible revenue range and substantial funding, Psilera is positioned to engage CROs, contract manufacturers, and suppliers for scalable synthesis, preclinical development, and phase-appropriate manufacturing as they advance toward the clinic.